Bioelectronics Corp (BIEL)

[art2426]

This was no test, no trial. The UK has already been satisfied on their requirements to sell products in their country. They are totally aware of their safety and efficacy. And so has the FDA, so there is no need for a 'large sample size'. The NHS wanted the company to show them how it would be of benefit to them (NHS) for reimbursement to its citizens for the cost of buying/using the Actipatch. There is no stipulation as to the number of samples required for that. It is simple statistics, math and projection as to the benefit of the Actipatch reimbursement by the NHS when comparing that number to what they are now reimbursing for so many other pain therapies. How using the actipatch will eliminate much of those other expenses for pain, thus benefiting the NHS financially. No need for large sample size when projection is the key.